Magi Khalil, MD, Oncology, Bellamy, VA, Riverside Regional Medical Center

MagiMagdiKhalilMDPhD

Oncology Bellamy, VA

Physician

Dr. Khalil is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Khalil's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 2004 - 2007
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2004
  • Albert Einstein College of Medicine, Yeshiva UniversityPhD, 1993 - 2001
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2001
  • Albert Einstein College of Medicine, Yeshiva UniversityMS, 1993 - 1995
  • Barnard College, Columbia UniversityBA, 1989 - 1993

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2011 - 2022
  • NJ State Medical License
    NJ State Medical License 2007 - 2011
  • NY State Medical License
    NY State Medical License 2007 - 2012
  • PA State Medical License
    PA State Medical License 2003 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Practice Excellence Award Riverside Medical Group, 2013
  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
  • Nominated for the 2007 NCCN Fellows Recognition Program 2007
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient...  
    Vonderheide, R.H., LoRusso, P.M., Khalil, M., Gartner, E.M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J.A., Rüter, J., Mariani, G.L., Usari, T., Domchek, S.M., Clin Cancer Res, 1/1/2010
  • Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts  
    Kim, S.J., Caton, M., Wang, C., Khalil, M., Zhou, Z., Hardin, J., and Diamond, B., J. of Exp. Med., 1/1/2008
  • Clinical Activity and Immune Modulation in Cancer Patients Treated with CP-870,893, A Novel CD40 Agonist Monoclonal Antibody  
    Vonderheide, R.H., Flaherty, K.T., Khalil, M., Schachter, M.S., Bajor, M., Gallagher, M., Sullivan, P., Mahaney, J.J., O’Dwyer, P., Huhn, R.D., and Antonia, S.J., J. Clin. Onc., 1/1/2007
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer.
    Vonderheide, R.H., LoRusso, P.M., Khalil, M., Heath, E., Khaira, D., Soulieres, D., Dorazio, P., Mariani, G.L., Usari, T., and Domchek, S.M., Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, 5/29/2009
  • “The Role of EGFR in the Prognosis and Treatment of NSCLC”
    Khalil MM, MSKCC Junior Faculty Conference, Basking Ridge, NJ, 12/16/2008
  • “Clinical Activity and Immune Modulation in Cancer Patients Treated with a Novel CD40 Agonist Monoclonal Antibody”
    Khalil MM, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 12/18/2006
  • Join now to see all

Lectures

  • “Clinical Activity and Immune Modulation in Cancer Patients Treated with a Novel CD40 Agonist Monoclonal Antibody” - Medicine Grand Rounds 
    Penn State Milton S. Hershey Medical Center, Hershey, PA - 11/9/2006

Press Mentions

  • Institute for Clinical Immuno-Oncology (ICLIO) Delivers Immunotherapy Education in the Community Setting
    Institute for Clinical Immuno-Oncology (ICLIO) Delivers Immunotherapy Education in the Community SettingJune 7th, 2017

Hospital Affiliations